Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-1 phase II tamibarotene study in relapsed or refractory acute promyelocytic leukemia after ATRA and arsenic trioxide
2007-002183-99Phase 2Active
- Sponsor
- Innovive Pharmaceuticals, Inc.
- Start
- Jul 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamibarotene in Acute promyelocytic leukaemia (APL), sponsored by Innovive Pharmaceuticals, Inc. Primary endpoint: Durable complete response rate. Started Jul 2007; status: active.
02
Drugs
tamibarotene
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2007-002183-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002183-99.